Randox Toxicology
Randox Toxicology Ltd. is a private Northern Ireland-headquartered diagnostics company that develops, manufactures, and globally distributes the patented Biochip Array Technology platform and Evidence Series analysers for multiplex forensic, post-mortem, clinical, and workplace toxicology testing, serving government forensic labs, medical examiner offices, hospitals, and academic institutions across more than 14 countries.
- Company typePrivate
- Founded2011
- HeadquartersCrumlin, United Kingdom
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Randox Toxicology does
Randox Toxicology Ltd. is a private Northern Ireland-headquartered diagnostics company and associate of Randox Laboratories, specialising in multiplex immunoassay solutions for forensic, post-mortem, clinical, and workplace toxicology. The company develops, manufactures, and globally distributes the patented Biochip Array Technology platform, which enables simultaneous detection of up to 48 analytes from a single sample using competitive chemiluminescent immunoassays read by digital imaging, supported by what the company describes as the world's largest toxicology test menu covering 600+ drugs and drug metabolites.
The product portfolio is anchored by the Evidence Series analyser family — the semi-automated Evidence Investigator, the fully automated benchtop Evidence MultiSTAT, and the next-generation random-access Evidence RABTA — complemented by ToxPlex 29-analyte panels, dedicated drugs-of-abuse (DoA) and new psychoactive substance (NPS) arrays, therapeutic drug monitoring biochips, ELISA kits, and supporting instrumentation. First-to-market assays for emerging threats such as xylazine (2023), nitazenes (2025), and organophosphates (2025) demonstrate a continuous R&D cadence, with content breadth cited as a key competitive differentiator versus single-analyte alternatives.
Commercially, Randox Toxicology operates a direct enterprise sales motion targeting coroners' offices, forensic and hospital laboratories, reference labs, government agencies, and academic institutions across at least 14 countries, supplemented by distributor channels, grant-funded acquisition programmes in the USA and Canada tied to opioid settlement funds, and multilingual digital marketing. Revenue is generated through one-time analyser equipment sales and a recurring consumables stream from proprietary biochips, ELISA kits, and quality control materials, with quote-based multi-year enterprise contracts and no public pricing. The company employs 51-100 staff and benefits from the broader R&D, manufacturing, and distribution infrastructure of its parent, Randox Laboratories.
Randox Toxicology firmographics
Firmographics- Name
- Randox Toxicology
- Legal name
- Randox Toxicology Ltd.
- Website
- https://randoxtoxicology.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Randox Toxicology Ltd. is a private Northern Ireland-headquartered diagnostics company that develops, manufactures, and globally distributes the patented Biochip Array Technology platform and Evidence Series analysers for multiplex forensic, post-mortem, clinical, and workplace toxicology testing, serving government forensic labs, medical examiner offices, hospitals, and academic institutions across more than 14 countries.
- Ownership category
- akta.pro rank
Randox Toxicology industry classification
Industry- Product category
- Toxicology Diagnostic Instruments
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)
Keywords
Where Randox Toxicology is headquartered
LocationHeadquarters
- HQ city
- Crumlin
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
Randox Toxicology business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Analyser Equipment Sales and Leasing: Sale and potentially leasing of Evidence Series analysers including Evidence Investigator, Evidence MultiSTAT, and Evidence RABTA to laboratories and forensic facilities.
- Biochip Test Kits and Reagents: Consumable revenue from proprietary biochip arrays and reagents for drug detection across 600+ analytes. Includes DoA arrays, NPS arrays, ToxPlex panels, and TDM assays.
- ELISA Test Kits: Sale of ELISA kits for drugs of abuse detection in various biological specimens with excellent correlation to confirmatory methods.
- Quality Control Materials: Dedicated multi-analyte reagents and quality control material providing reliable and controlled testing for laboratory compliance.
- Grant-Funded Equipment Programs: Evidence MultiSTAT analyser sales facilitated through government opioid settlement grants in USA and Canada for harm reduction and drug surveillance initiatives.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Enterprise/Custom Pricing |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels9 records
Randox Toxicology product offering
Product offeringCore offering
Randox Toxicology manufactures and sells proprietary Biochip Array Technology-based analytical instruments (Evidence Investigator, Evidence MultiSTAT, Evidence RABTA) and a suite of consumable test kits covering more than 600 drug and metabolite assays for forensic, post-mortem, clinical, and workplace drug screening. The company supplies ELISA kits, biochip test arrays, and the 800TS plate reader to laboratories worldwide, enabling multiplex screening across multiple sample matrices.
Product overview
Randox Toxicology delivers a platform-plus-products portfolio built around its proprietary Biochip Array Technology, a patented multiplex immunoassay testing platform that enables simultaneous multi-analyte detection from a single sample. The core analyser family, called the Evidence Series, includes three distinct instruments: the Evidence Investigator (semi-automated benchtop), the Evidence MultiSTAT (fully automated benchtop), and the Evidence RABTA (next-generation random-access analyser). These platforms are complemented by a comprehensive test menu exceeding 600 drugs and drug metabolites across multiple product lines including DoA Arrays (Drugs of Abuse I+, Ultra, Hair), NPS Arrays (New Psychoactive Substances), ToxPlex Array (29-analyte panel), TDM Arrays (Therapeutic Drug Monitoring), and specialized arrays for Nitazenes, Organophosphates, and Xylazine. The company also offers standalone ELISA kits and the 800TS plate reader for laboratories preferring traditional immunoassay workflows.
Differentiator
Problem solved
Functional benefit
Brands
- Biochip Array Technology: Patented multiplex immunoassay testing platform enabling simultaneous multi-analyte detection from a single sample
- Evidence Series
- Evidence MultiSTAT
- Evidence RABTA
- Evidence Investigator
- ToxPlex
- ELISA Kits
Products and services
- Evidence Investigator
Quantifiable outcome
- Turnaround time reduced from 6-8 weeks to under 30 minutes for post-mortem toxicology
- +5 more outcomes
Companies that use Randox Toxicology
Customer profileNamed customers16 records
Segments6 records
Ideal customer profiles4 records
Randox Toxicology technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Randox Toxicology partnerships and signals
Strategic signalScale indicators5 records
Recent moves6 records
Expansion highlights6 records
Randox Toxicology competitors and assessment
Company assessmentBroad incumbents
- Waters Corporation:
- Thermo Fisher Scientific: Global leader in analytical instruments and IVD reagents with significant presence in forensic and clinical toxicology through its mass spectrometry and immunoassay portfolios; competes with Randox across both hardware and consumables in toxicology labs worldwide.
- Agilent Technologies: Leading analytical instrument and consumables provider with deep forensic toxicology presence through mass spec, GC, and LC systems; competes with Randox in reference and government forensic lab procurement.
Direct peers
- SCIEX: Danaher-owned specialist in mass spectrometry for forensic, clinical, and research toxicology; competes head-to-head with Randox's Evidence Series in drug screening workflows, particularly for confirmatory testing and high-throughput reference labs.
- Shimadzu Corporation: Major analytical instrument manufacturer with strong mass spectrometry and chromatography footprint in forensic toxicology; offers competing high-throughput screening and confirmation solutions used by police and forensic laboratories globally.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Randox Toxicology social profiles
Digital presenceRandox Toxicology financial estimates
Financial estimateRevenue estimate
Valuation estimate
Randox Toxicology leadership team
Management profileNumber of profiles
Randox Toxicology funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Randox Toxicology M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Randox Toxicology
What does Randox Toxicology do?
Randox Toxicology manufactures and sells proprietary Biochip Array Technology-based analytical instruments (Evidence Investigator, Evidence MultiSTAT, Evidence RABTA) and a suite of consumable test kits covering more than 600 drug and metabolite assays for forensic, post-mortem, clinical, and workplace drug screening. The company supplies ELISA kits, biochip test arrays, and the 800TS plate reader to laboratories worldwide, enabling multiplex screening across multiple sample matrices.
Is Randox Toxicology a public or private company?
Randox Toxicology is a private company. It is classified as corporate owned and is currently operating.
When was Randox Toxicology founded?
Randox Toxicology was founded in 2011. It employs 51 to 100 people.
Where is Randox Toxicology based?
Randox Toxicology is headquartered in Crumlin, United Kingdom, in the Europe region.
How does Randox Toxicology make money?
Five revenue lines are on record. Analyser Equipment Sales and Leasing is the primary driver. The others are biochip Test Kits and Reagents, ELISA Test Kits, quality Control Materials and grant-Funded Equipment Programs.
Who are Randox Toxicology's main competitors?
Broad incumbents on record are Waters Corporation, Thermo Fisher Scientific and Agilent Technologies. Direct peers are SCIEX and Shimadzu Corporation.
Does Randox Toxicology have an API?
No public API is recorded for Randox Toxicology.
What industry is Randox Toxicology in?
Randox Toxicology's product category is Toxicology Diagnostic Instruments. Its primary akta.pro industry code is HLAGAIAI, Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes). Its NAICS code is 325413 and its SIC code is 2835.